J-P. Metges

Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer

Laure Gibault, J-P. Metges, Virginie Conan‐Charlet et al. · British Journal of Cancer · 2005 · 145 citations · Full text

Surgical Oncology, Reduced Overall Survival, Esophageal Cancer +19

LBA8_PR Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study

Ken Kato, J-M. Sun, Manan Shah et al. · Annals of Oncology · 2020 · 130 citations

Advanced Esophageal Cancer, Esophagus, Esophageal Cancer +7

PANERB study: Panitumumab after cetuximab-based regimen failure.

J-P. Metges, Jean‐Luc Raoul, Nacredine Achour et al. · Journal of Clinical Oncology · 2010 · 38 citations

Panerb Study, Medicine, Cancer Management +11

LBA45 Randomized open label phase III study comparing the efficacy and safety of everolimus followed by chemotherapy (CT) with streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs: The SEQTOR study (GETNE 1206)

Ramón Salazar, S. Tafuto, Merete Krogh et al. · Annals of Oncology · 2022 · 30 citations · Full text

Advanced Progressive Pannets, Seqtor Study, Reverse Sequence +11

1400O Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G/GEJ adenocarcinoma

Y. Y. Janjigian, Akihito Kawazoe, Yikui Bai et al. · Annals of Oncology · 2024 · 30 citations · Full text

Medicine, Phase Iii, Immunology +7